“We must recognise that unvaccinated people are unlikely to cause any more risk to others than the vaccinated, and perhaps less.”
In a recent hearing of the UK Pandemic Response and Recovery All Party Parliamentary Group, several experts said they were highly sceptical of the value of vaccine passports.
Professor David Paton:
“There is no obvious sign from countries that have already implemented similar certification schemes that there are any benefits in terms of reducing infections. But we know there will be huge costs to the economy; nightclubs in Scotland have reported trade levels dropping by almost half since the introduction of their vaccine passport scheme while leaked documents show that the Government itself estimates the cost of implementing Plan B in England to be between £11 billion and £18 billion.
Covid passes are a heavy-handed and invasive approach to public health. They pose an unacceptable risk to rights and individual liberties and could jeopardise trust in public health measures at a critical time.”
Dr Roland Salmon said:
“From a public health standpoint, it makes little sense to impose any kind of vaccine certification scheme. If the vaccine is to protect others around you, then it needs to greatly reduce transmission. Studies from Public Health England and Imperial College only show reductions in household transmission of 30-50%; not enough and even then, probably temporary. Thus, a policy of targeting vaccination to those at highest risk, allowing broader post-infection immunity to develop in the wider community to prevent spread is likely to be a much more effective approach.”
Dr David Bell:
“It is unclear what vaccine passports will achieve in the U.K. We must recognise that unvaccinated people are unlikely to cause any more risk to others than the vaccinated, and perhaps less. We know that vaccinated people who become infected commonly have similar infectiousness as unvaccinated people, while Public Health England data indicates that vaccinated people over 30 years are now more likely to be infected than the unvaccinated. We also know that unvaccinated people will, in general, suffer more symptoms, so are more likely to abstain from community gatherings when infected, while infected vaccinated people continue to be active, potentially increasing risk to the vulnerable.”
This study provided in vivo evidence that inadvertent intravenous injection of COVID-19 mRNA vaccines may induce myopericarditis. Brief withdrawal of syringe plunger to exclude blood aspiration may be one possible way to reduce such risk.
See also: “The middle of the vastus lateralis is an appropriate site for intramuscular injections because of the low risk of vascular or nerve damage.”
Turkey’s Health Ministry has announced that health workers and priority groups are now eligible to receive a fourth dose of the COVID-19 vaccine as part of the country’s efforts to combat the resurgence of the disease.
The individuals in these groups who have previously had two doses of the Chinese-produced CoronaVac followed by one dose of the Pfizer/BioNTech vaccine as a booster shot will be able to get one more dose of the Pfizer/BioNTech vaccine.
On July 1 the Health Ministry started to offer a third dose of COVID-19 vaccines for people aged 50 and above and health workers who previously had two doses as part of its vaccination drive.
A study conducted in Hong Kong on more than a thousand patients shows that the Coronavac vaccine, developed by the Chinese laboratory Sinovac, causes the production of ten times less antibodies than the vaccine developed by BioNTech and produced by Pfizer.
This comparison between the two vaccines available in Hong Kong was conducted by researchers at the University of Hong Kong on 1,442 health workers who received two doses of these vaccines.
Published in the medical journal The Lancet Microbe on July 15, the article specifies that the quantity of antibodies is not sufficient to assess the level of immunity conferred by a vaccine, but that “the differences in the concentrations of neutralizing antibodies identified in our study could result in substantial differences in vaccine efficacy ”. The researchers add that patients who received Coronavac show similar antibody levels to patients who contracted Covid-19 and are cured.
“We also observed that the spike protein of the Lambda variant presented increased infectivity when compared with the spike protein of the Alpha and Gamma variants, both of them with reported increased infectivity and transmissibility. Together, our data show for the first time that mutations present in the spike protein of the Lambda variant confer escape to neutralizing antibodies and increased infectivity.”
“The evidence presented here reinforces the idea that massive vaccination campaigns in countries with high SARS-CoV-2 circulation rates must be accompanied by strict genomic surveillance aimed to rapidly identify new viral isolates carrying spike mutations as well as studies aimed to analyze the impact of these mutations in immune escape and vaccines breakthrough.”